Progression-Free Survival Increased Fivefold, Intracranial Response Rate at 65.7%! ‘Miraculous Anti-Cancer Drug’ Solves the Treatment Challenge of Breast Cancer Brain Metastases
What else can DS-8201 not do? Recently, the “miraculous anti-cancer drug” DS-8201 announced data from its DESTINY-Breast03 trial involving patients with brain metastases[1]: Among 43 patients with HER2-positive breast cancer brain metastases treated with DS-8201, the median progression-free survival reached 15.0 months, with intracranial objective response rate and overall objective response rate at 65.7% and … Read more
